In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration today approved a personalized cellular therapy developed by the University of Pennsylvania and Children’s Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Read More